FIGURE 2.

Annual rate of on-treatment a) moderate or severe and b) severe exacerbations (post-hoc analysis) according to exacerbation history in the year prior to screening for each treatment comparison. The exacerbation history subgroups are defined as single moderate (1 moderate/no severe exacerbation in the prior year), frequent moderate (≥2 moderate/no severe exacerbations in the prior year) and severe (≥1 severe/any moderate exacerbation in the prior year). Data are presented as model estimated annual rate (95% CI), unless otherwise stated. FF: fluticasone furoate; RR: rate ratio; UMEC: umeclidinium; VI: vilanterol.